{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T17:55:25Z","timestamp":1772819725347,"version":"3.50.1"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,8,26]],"date-time":"2014-08-26T00:00:00Z","timestamp":1409011200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1245\/s10434-014-4026-6","type":"journal-article","created":{"date-parts":[[2014,8,25]],"date-time":"2014-08-25T13:20:22Z","timestamp":1408972822000},"page":"655-661","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Carcinoma: Analysis of 30-Day Morbidity and Mortality"],"prefix":"10.1245","volume":"22","author":[{"given":"James","family":"Cripe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jill","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramez","family":"Eskander","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda Nickles","family":"Fader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward","family":"Tanner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bristow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,26]]},"reference":[{"issue":"1","key":"4026_CR1","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3322\/caac.21166","volume":"63","author":"R Siegel","year":"2013","unstructured":"Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63(1):11\u201330. doi: 10.3322\/caac.21166 .","journal-title":"CA Cancer J Clin."},{"issue":"17","key":"4026_CR2","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21(17):3194\u2013200. doi: 10.1200\/JCO.2003.02.153 .","journal-title":"J Clin Oncol."},{"issue":"5","key":"4026_CR3","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","volume":"20","author":"R Bristow","year":"2002","unstructured":"Bristow R, Tomacruz R. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248\u20131259.","journal-title":"J Clin Oncol."},{"issue":"2","key":"4026_CR4","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/S0090-8258(03)00278-6","volume":"90","author":"S Eisenkop","year":"2003","unstructured":"Eisenkop S, Spirtos N, Friedman R. Relative influences of tumor volume before surgery and the cytoreductive outcome on survival for patients with advanced ovarian cancer: a prospective study. Gynecol Oncol. 2003;90(2):390\u2013396. doi: 10.1016\/S0090-8258(03)00278-6 .","journal-title":"Gynecol Oncol."},{"issue":"1","key":"4026_CR5","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","volume":"354","author":"D Armstrong","year":"2006","unstructured":"Armstrong D, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34\u201343.","journal-title":"N Engl J Med."},{"issue":"1","key":"4026_CR6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ygyno.2013.04.001","volume":"130","author":"LM Landrum","year":"2013","unstructured":"Landrum LM, Java J, Mathews CA, et al. Prognostic factors for stage III epithelial ovarian cancer treated with intraperitoneal chemotherapy: a Gynecologic Oncology Group study. Gynecol Oncol. 2013;130(1):12\u20138. doi: 10.1016\/j.ygyno.2013.04.001 .","journal-title":"Gynecol Oncol."},{"issue":"1","key":"4026_CR7","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11864-013-0264-2","volume":"15","author":"RN Eskander","year":"2014","unstructured":"Eskander RN, Cripe J, Bristow RE. Intraperitoneal chemotherapy from Armstrong to HIPEC: challenges and promise. Curr Treat Options Oncol. 2014;15(1):27\u201340. doi: 10.1007\/s11864-013-0264-2 .","journal-title":"Curr Treat Options Oncol."},{"issue":"1\u20132","key":"4026_CR8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0960-7404(99)00007-9","volume":"7","author":"C Christophi","year":"1998","unstructured":"Christophi C, Winkworth A, Muralihdaran V, Evans P. The treatment of malignancy by hyperthermia. Surg Oncol. 1998;7(1\u20132):83\u201390.","journal-title":"Surg Oncol."},{"issue":"12","key":"4026_CR9","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1093\/annonc\/mdm137","volume":"18","author":"L Bijelic","year":"2007","unstructured":"Bijelic L, Jonson A, Sugarbaker PH. Systematic review of cytoreductive surgery and heated intraoperative intraperitoneal chemotherapy for treatment of peritoneal carcinomatosis in primary and recurrent ovarian cancer. Ann Oncol. 2007;18(12):1943\u201350. doi: 10.1093\/annonc\/mdm137 .","journal-title":"Ann Oncol."},{"issue":"1","key":"4026_CR10","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0959-8049(97)00370-5","volume":"34","author":"PJ Vaart van de","year":"1998","unstructured":"van de Vaart PJ, van der Vange N, Zoetmulder FA, et al. Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin\u00a0\u00b1\u00a0DNA adduct formation in patients and ovarian cancer cell lines. Eur J Cancer. 1998;34(1):148\u2013154.","journal-title":"Eur J Cancer."},{"issue":"1","key":"4026_CR11","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00000658-199501000-00004","volume":"221","author":"P Sugarbaker","year":"1995","unstructured":"Sugarbaker P. Peritonectomy procedures. Ann Surg. 1995;221(1):29\u201342.","journal-title":"Ann Surg."},{"issue":"2","key":"4026_CR12","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/cncr.23553","volume":"113","author":"A Giorgio Di","year":"2008","unstructured":"Di Giorgio A, Naticchioni E, Biacchi D, et al. Cytoreductive surgery (peritonectomy procedures) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of diffuse peritoneal carcinomatosis from ovarian cancer. Cancer. 2008;113(2):315\u201325. doi: 10.1002\/cncr.23553 .","journal-title":"Cancer."},{"issue":"8","key":"4026_CR13","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1007\/s10434-999-0790-0","volume":"6","author":"AD Stephens","year":"1999","unstructured":"Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol. 1999;6(8):790\u20136.","journal-title":"Ann Surg Oncol."},{"key":"4026_CR14","doi-asserted-by":"crossref","unstructured":"Aletti GD, Dowdy SC, Podratz KC, Cliby WA. Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer. Am J Obstet Gynecol. 2007;197(6):676.e1\u20137. doi: 10.1016\/j.ajog.2007.10.495 .","DOI":"10.1016\/j.ajog.2007.10.495"},{"issue":"2","key":"4026_CR15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ygyno.2010.07.017","volume":"119","author":"S Bashir","year":"2010","unstructured":"Bashir S, Gerardi MA, Giuntoli RL, Montes TPD, Bristow RE. Surgical technique of diaphragm full-thickness resection and trans-diaphragmatic decompression of pneumothorax during cytoreductive surgery for ovarian cancer. Gynecol Oncol. 2010;119(2):255\u20138. doi: 10.1016\/j.ygyno.2010.07.017 .","journal-title":"Gynecol Oncol."},{"issue":"2","key":"4026_CR16","first-page":"256","volume":"40","author":"JS Spratt","year":"1980","unstructured":"Spratt JS, Adcock RA, Muskovin M, Sherrill W, Mckeown J. Clinical delivery system for intraperitoneal hyperthermic chemotherapy clinical delivery system for intraperitoneal hyperthermic chemotherapy. Cancer Res. 1980;40(2):256\u2013260.","journal-title":"Cancer Res."},{"issue":"3","key":"4026_CR17","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.ygyno.2012.09.020","volume":"127","author":"A Fagotti","year":"2012","unstructured":"Fagotti A, Costantini B, Petrillo M. Cytoreductive surgery plus HIPEC in platinum-sensitive recurrent ovarian cancer patients: a case\u2013control study on survival in patients with two year follow-up. Gynecol Oncol. 2012;127(3):502\u20135. doi: 10.1016\/j.ygyno.2012.09.020 .","journal-title":"Gynecol Oncol."},{"issue":"2","key":"4026_CR18","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2011.05.004","volume":"122","author":"M Deraco","year":"2011","unstructured":"Deraco M, Kusamura S, Virz\u00ec S, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy as upfront therapy for advanced epithelial ovarian cancer: multi-institutional phase-II trial. Gynecol Oncol. 2011;122(2):215\u2013220. doi: 10.1016\/j.ygyno.2011.05.004 .","journal-title":"Gynecol Oncol"},{"issue":"7","key":"4026_CR19","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1245\/s10434-014-3599-4","volume":"21","author":"PA Cascales-Campos","year":"2014","unstructured":"Cascales-Campos PA, Gil J, Gil E, et al. Treatment of microscopic disease with hyperthermic intraoperative intraperitoneal chemotherapy after complete cytoreduction improves disease-free survival in patients with stage IIIC\/IV ovarian cancer. Ann Surg Oncol. 2014;21(7):2383\u20132389. doi: 10.1245\/s10434-014-3599-4 .","journal-title":"Ann Surg Oncol."},{"issue":"25","key":"4026_CR20","doi-asserted-by":"crossref","first-page":"3793","DOI":"10.2174\/138161212802002616","volume":"18","author":"S Mulier","year":"2012","unstructured":"Mulier S, Claes J, Dierieck V. Survival benefit of adding hyperthermic intraperitoneal chemotherapy (HIPEC) at the different time-points of treatment of ovarian cancer: review of evidence. Curr Pharm Des. 2012;18(25):3793\u20133803.","journal-title":"Curr Pharm Des."},{"issue":"12","key":"4026_CR21","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1007\/s00432-009-0667-4","volume":"135","author":"T Chua","year":"2009","unstructured":"Chua T, Robertson G, Liauw W. Intraoperative hyperthermic intraperitoneal chemotherapy after cytoreductive surgery in ovarian cancer peritoneal carcinomatosis: systematic review of current results. J Cancer Res Clin Oncol. 2009;135(12):1637\u201345. doi: 10.1007\/s00432-009-0667-4 .","journal-title":"J Cancer Res Clin Oncol."},{"issue":"7","key":"4026_CR22","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ejso.2013.02.018","volume":"39","author":"N Bakrin","year":"2013","unstructured":"Bakrin N, Gilly FN, Baratti D, et al. Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients. Eur J Surg Oncol. 2013;39(7):742\u20137. doi: 10.1016\/j.ejso.2013.02.018 .","journal-title":"Eur J Surg Oncol."},{"issue":"12","key":"4026_CR23","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1016\/j.ejso.2013.09.030","volume":"39","author":"N Bakrin","year":"2013","unstructured":"Bakrin N, Bereder JM, Decullier E, et al. Peritoneal carcinomatosis treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for advanced ovarian carcinoma: a French multicentre retrospective cohort study of 566 patients. Eur J Surg Oncol. 2013;39(12):1435\u201343. doi: 10.1016\/j.ejso.2013.09.030 .","journal-title":"Eur J Surg Oncol."},{"issue":"13","key":"4026_CR24","doi-asserted-by":"crossref","first-page":"4052","DOI":"10.1245\/s10434-012-2510-4","volume":"19","author":"N Bakrin","year":"2012","unstructured":"Bakrin N, Cotte E, Golfier F, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) for persistent and recurrent advanced ovarian carcinoma: a multicenter, prospective study of 246 patients. Ann Surg Oncol. 2012;19(13):4052\u20138. doi: 10.1245\/s10434-012-2510-4 .","journal-title":"Ann Surg Oncol."},{"issue":"2","key":"4026_CR25","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.ygyno.2011.04.008","volume":"122","author":"A Fagotti","year":"2011","unstructured":"Fagotti A, Costantini B, Vizzielli G, et al. HIPEC in recurrent ovarian cancer patients: morbidity-related treatment and long-term analysis of clinical outcome. Gynecol Oncol. 2011;122(2):221\u20135. doi: 10.1016\/j.ygyno.2011.04.008 .","journal-title":"Gynecol Oncol."},{"issue":"5","key":"4026_CR26","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1097\/IGC.0b013e31824d836c","volume":"22","author":"L Ansaloni","year":"2012","unstructured":"Ansaloni L, Agnoletti V, Amadori A, et al. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer. 2012;22(5):778\u201385. doi: 10.1097\/IGC.0b013e31824d836c .","journal-title":"Int J Gynecol Cancer."},{"issue":"7","key":"4026_CR27","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00423-011-0835-2","volume":"396","author":"I K\u00f6nigsrainer","year":"2011","unstructured":"K\u00f6nigsrainer I, Beckert S, Becker S. Cytoreductive surgery and HIPEC in peritoneal recurrent ovarian cancer: experience and lessons learned. Langenbecks Arch Surg. 2011;396(7):1077\u20131081. doi: 10.1007\/s00423-011-0835-2 .","journal-title":"Langenbecks Arch Surg."},{"key":"4026_CR28","unstructured":"ClinicalTrials.gov., a service of the US National Institutes of Health. https:\/\/clinicaltrials.gov\/ct2\/results?term=HIPEC%2C+ovarian+cancer&show_down=Y . Accessed 27 Jun 2014."},{"issue":"1","key":"4026_CR29","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.ygyno.2013.01.010","volume":"129","author":"PA Argenta","year":"2013","unstructured":"Argenta PA, Sueblinvong T, Geller MA, et al. Hyperthermic intraperitoneal chemotherapy with carboplatin for optimally-cytoreduced, recurrent, platinum-sensitive ovarian carcinoma: a pilot study. Gynecol Oncol. 2013;129(1):81\u20135. doi: 10.1016\/j.ygyno.2013.01.010 .","journal-title":"Gynecol Oncol."},{"issue":"7","key":"4026_CR30","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/j.1471-0528.2011.03207.x","volume":"119","author":"M Deraco","year":"2012","unstructured":"Deraco M, Virz\u00ec S, Iusco D. Secondary cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer: a multi-institutional study. BJOG. 2012;119(7):800\u2013809. doi: 10.1111\/j.1471-0528.2011.03207.x .","journal-title":"BJOG."},{"key":"4026_CR31","unstructured":"Carrabin N, Mithieux F, Meeus P. Hyperthermic intraperitoneal chemotherapy with oxaliplatin and without adjuvant chemotherapy in stage IIIC ovarian cancer. Bull Cancer. 2010;97:1\u201310. Available at: http:\/\/www.jle.com\/e-docs\/00\/04\/57\/15\/article.phtml . Accessed 27 Jul 2014."},{"issue":"6","key":"4026_CR32","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/jso.21682","volume":"102","author":"F Roviello","year":"2010","unstructured":"Roviello F, Pinto E, Corso G. Safety and potential benefit of hyperthermic intraperitoneal chemotherapy (HIPEC) in peritoneal carcinomatosis from primary or recurrent ovarian cancer. J Surg Oncol. 2010;102(6):663\u2013670. doi: 10.1002\/jso.21682 .","journal-title":"J Surg Oncol."},{"key":"4026_CR33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ygyno.2007.03.022","volume":"106","author":"S Lentz","year":"2007","unstructured":"Lentz S, Miller B, Kucera G, Levine E. Intraperitoneal hyperthermic chemotherapy using carboplatin: a phase I analysis in ovarian carcinoma. Gynecol Oncol. 2007;106:207\u2013210. doi: 10.1016\/j.ygyno.2007.03.022 .","journal-title":"Gynecol Oncol."},{"issue":"1","key":"4026_CR34","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ygyno.2007.03.019","volume":"106","author":"JH Bae","year":"2007","unstructured":"Bae JH, Lee JM, Ryu KS, et al. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol. 2007;106(1):193\u2013200. doi: 10.1016\/j.ygyno.2007.03.019 .","journal-title":"Gynecol Oncol."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-4026-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1245\/s10434-014-4026-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-014-4026-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T07:24:31Z","timestamp":1559633071000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1245\/s10434-014-4026-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,26]]},"references-count":34,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["4026"],"URL":"https:\/\/doi.org\/10.1245\/s10434-014-4026-6","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,26]]}}}